On August 27, Moderna, Inc. fell 3.27% in pre-market trading, trading at $144.7/share, with turnover of $12.47 million. The decline follows a 4.85% intraday drop and 1% after-hours slide in the prior session, extending the pattern of volatile repricing after the stock's historic 177% surge on mRNA cancer vaccine trial success.

The stock had rallied over 14% on August 25 after Wolfe Research upgraded its rating to peer perform, but immediately faced selling pressure. UBS previously reported that clients net sold $44 million of Moderna shares on the day of the initial surge, and profit-taking continues to weigh on the stock. Since the breakthrough announcement of its personalized mRNA cancer vaccine intismeran autogene achieving positive Phase III results in melanoma, the stock has experienced a 23.5% pullback, a 16% rebound, another 14% rally, and subsequent retreats. Options market implied volatility remains at the 99.6th percentile, reflecting intense bull-bear contestation as the market digests the fundamental re-rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)